Matthew Walsh Chief Financial Officer (CFO) Organon & Co.

In his new role at Organon & Co., Matthew will be responsible for the development and execution of the company’s overall financial strategy, and will oversee corporate financial planning, treasury, tax, audit, investor relations and business development.

Matt Walsh joins Organon from Allergan, where he served as Executive Vice President and Chief Financial Officer since February 2018. Matt is a seasoned finance executive with over 15 years of public company CFO experience. He brings a healthcare background from his prior role with Allergan and from Catalent, where he served as EVP, CFO for 10 years. Matt has notable expertise in mergers and acquisitions, with extensive experience throughout his career, including 11 acquisitions and integrations and five divestitures during his tenure at Catalent.

Before Catalent, Matt was President, CFO and Acting CEO at Escala Group, Inc. He previously held a variety of finance leadership roles at GenTek, Inc., including Vice President-Finance & Chief Financial Officer, Vice President & Treasurer and Group Controller.

Matt received a Master of Business Administration from Cornell University, SC Johnson Graduate School of Management and a Bachelor of Science in Chemical Engineering from Cornell University, College of Engineering.

-------------------------------------------------------------------------------------------------------------------------------------------------For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through Merck’s prescription medicines, vaccines, biologic therapies and animal health products, the company works with customers and operates in more than 140 countries to deliver innovative health solutions. Merck also demonstrates our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world — including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases, including HIV and Ebola. For more information, visit www.merck.com and connect with Merck on Twitter, Facebook, YouTube and LinkedIn.

May 2020